Thanks very much, Madam Chair.
My first question is in relation to the approval process for vaccines. Obviously, without domestic manufacturing capacity, we rely on imports and so, out of necessity, it is really important to approve these vaccines as quickly as possible.
A constituent of mine, Dr. Doan, asked why there has been a delay in approving AstraZeneca, and when we look at the EU and Australia and the U.K., why, in a crisis situation like this, a global pandemic, would we not rely upon not a single international regulator. When there is a collection of trusted regulators, three that I've referenced, why on that basis would we not expedite the approval of these critical vaccines?